What's next for Roche, which is projected to lose top spot in the cancer-drug market as sales of its key medicines decline and rivals pile into the sector?
Many pharmaceutical companies expect cancer treatments to drive growth in the coming years. One notable exception: the world’s largest cancer-drug maker.
Switzerland’s Roche Holding AG has enjoyed almost two decades as an unrivaled force in oncology. Now, with more companies piling into the space and its top-selling drugs losing sales to lower-cost copies, that is about to change.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Merck's Keytruda no better than chemo as a first-line treatment for gastric cancer, according to Phase 3 study resultsMerck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of the drugmaker were down 0.05% in premarket trade. An earlier Phase 3 study looking at Keytruda as a second-line treatment for gastric cancer also failed to show a survival benefit, though the Food and Drug Administration did approve the drug in 2017 as a third-line treatment for patients with advanced gastric cancer. Keytruda is currently used for many other cancer indications, including treating certain subsets of patients with melanoma, lung cancer, Hodgkin lymphoma and cervical cancer, among many others. Shares of the pharmaceutical giant have fallen 0.1% in the year to date, while the S&P 500 has gained 16.7%.
Read more »
AstraZeneca: EU advises wider use for cancer drugAstraZeneca PLC (AZN.LN) said Monday that Europe's medicines regulator has recommended that the indication for the company's cancer drug Lynparza be expanded. The European Medicines Agency's Committee for Medicinal Products for Human Use has given the go-ahead for the use of Lynparza as a first-line maintenance treatment of advanced ovarian cancer with a mutation in the BRCA gene.
Read more »
Eli Lilly to Pull Cancer Drug From Market After Failed StudyEli Lilly plans to withdraw its cancer drug Lartruvo from the market after a study showed that it failed to prolong overall survival in a clinical trial.
Read more »
Merck's Keytruda wins FDA approval as combination therapy for kidney cancerThe U.S. Food and Drug Administration has approved Merck & Co Inc's cancer ...
Read more »
Roche faces further delay in $4.3 billion Spark deal amid FTC reviewRoche on Friday announced another extension of its $4.3 billion offer for gene t...
Read more »
Scientists with ties to China ousted from US cancer center amid fears of foreign influenceA leading cancer research center in Texas took action against a handful of faculty members for sharing confidential information and failing to disclose foreign ties, it says.
Read more »
Woman lied about having kidney cancer to steal fundraising money, police sayHannah Hume is accused of felony attempt to obtain property by false pretense after allegedly lying about kidney cancer.
Read more »
Medicare proposes higher payments for innovative cancer treatmentIf approved, the increased reimbursements for CAR T-cell therapy and “breakthrough” devices would go into effect on Oct. 1.
Read more »
Texas cancer center ousts 3 scientists over Chinese data theft concernsA prominent cancer center in Houston has ousted three of five scientists whom federal authorities identified as being involved in Chinese efforts to steal American research.
Read more »